LISTING OF THE CLAIMS

This listing of claims will replace all prior versions of the claims and listing of the claims in the application:

1.-13. **(Cancelled)**

14. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



(II)

in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group;

and pharmaceutically acceptable salts thereof.

15. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



(III)

in which

R_2 is hydrogen or alkyl;

R_3 is a bond or methylene; and

R_4 is aryl or aralkyl; or

R_2 and R_4-R_3 are joined to form, together with the methine to which they are attached, a cyclic or polycyclic group; and

R_5 is alkylene, alkenylene, alkynylene and alkoxylene;

and pharmaceutically acceptable salts thereof.

16. **(Previously Presented)** A method for treating a subject for glaucoma, comprising administering a therapeutically effective amount of a deprenyl compound to a subject, wherein the deprenyl compound is represented by the structure:



(IV)

in which

R_1 is hydrogen, alkyl, alkenyl, alkynyl, aralkyl, alkylcarbonyl, arylcarbonyl, alkoxycarbonyl, or aryloxycarbonyl;

A is a substituent independently selected for each occurrence from the group consisting of halogen, hydroxyl, alkyl, alkoxyl, cyano, nitro, amino, carboxyl, -CF_3, or azido;

n is 0 or an integer from 1 to 5;

and pharmaceutically acceptable salts thereof.

17.-20. **(Cancelled)**

21. **(Previously Presented)** The method of claim 14, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

22. **(Previously Presented)** The method of claim 21, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.

23. **(Previously Presented)** The method of claim 22, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.

24. **(Previously Presented)** The method of claim 21, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.

25. **(Previously Presented)** The method of claim 14, wherein said subject is a human.

26. **(Previously Presented)** The method of claim 15, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

27. **(Previously Presented)** The method of claim 26, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.

28. **(Previously Presented)** The method of claim 26, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.

29. **(Previously Presented)** The method of claim 28, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.

30. **(Previously Presented)** The method of claim 15, wherein said subject is a human.

31. **(Previously Presented)** The method of claim 16, wherein said therapeutically effective amount of a deprenyl compounds is administered with a pharmaceutically acceptable carrier.

32. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier has a pH of between about 3 and about 5.

33. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier is an alcohol or aqueous alcohol solution.

34. **(Previously Presented)** The method of claim 31, wherein said pharmaceutically acceptable carrier is suitable for ophthalmic administration.

35. **(Previously Presented)** The method of claim 16, wherein said subject is a human.